Butyric Acid

Butyric Acid

SCHEMBL719892

CCCC(=O)[O-].O=C([O-])O.[Na+].[Na+]

nearest known ligand 0.88

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Butyric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 3/20 0.88
HDAC3 O15379 3/20 0.88
HDAC1 Q13547 3/20 0.88
HDAC2 Q92769 3/20 0.88
HDAC8 Q9BY41 3/20 0.88
CA1 P00915 3/20 0.62
CES2 O00748 1/20 0.53
CES1 P23141 1/20 0.53
NFKB1 P19838 1/20 0.50
GPR84 Q9NQS5 1/20 0.48
CA2 P00918 1/20 0.45
FABP3 P05413 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butyric Acid SCHEMBL9298214 0.94 FFAR3 (0.88) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL5323747 0.94 FFAR3 (0.82) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL28375515 0.94 FFAR3 (1.00) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL1331084 0.94
Butyric Acid SCHEMBL28484953 0.94 FFAR3 (1.00) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL1330878 0.94
Butyric Acid SCHEMBL4292004 0.94 FFAR3 (1.00) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL1331797 0.94
Butyric Acid SCHEMBL1331463 0.94
Butyric Acid SCHEMBL1331447 0.94

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117886681-A Selective oxidation method for benzyl compound and allyl compound 合肥工业大学 2024-04-16 CN disclosed
US-8912338-B2 Pesticidal compositions Dow AgroScience, LLC. (US) 2014-12-16 US disclosed
US-20140057785-A1 PESTICIDAL COMPOSITIONS DOW AGROSCIENCES LLC (US) 2014-02-27 US disclosed
US-8604211-B2 Pesticidal compositions Dow AroSciecnes, LLC. (US) 2013-12-10 US disclosed
EP-2004182-B1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE GLAXO GROUP LTD (GB) 2013-05-08 EP disclosed
CN-1826333-B Diamine derivatives DAIICHI SANKYO CO LTD 2012-12-26 CN disclosed
US-20120053146-A1 PESTICIDAL COMPOSITIONS DOW AGROSCIENCES LLC 2012-03-01 US disclosed
CN-100545160-C Diamine derivative DAIICHI SEIYAKU CO (JP) 2009-09-30 CN disclosed
EP-1348706-B1 SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2009-08-19 EP disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
WO-1992015601-A2 HETEROANTHRACYCLINE ANTITUMOR ANALOGS BIOCHEM PHARMA, INC. (CA) 1992-09-17 WO disclosed
EP-0502661-A2 Heteroanthracycline anti-tumor analogues BIOCHEM PHARMA INC. (CA) 1992-09-09 EP disclosed
US-5137901-A For binding 5-HT 1 receptors; treating central nervous system disorders BAYER AKTIENGESELLSCHAFT (DE) 1992-08-11 US disclosed
EP-0399645-A2 Tetrahydropyranyl derivatives, process for their preparation and pharmaceutical or veterinary compositions containing them BEECHAM GROUP PLC (GB) 1990-11-28 EP disclosed
US-4960879-A REACTING SUBSTITUTED AZETIDINONE WITH TRANS SUBSTITUTED-METHYL ALKYLACRYLIC ACID AND REDUCING METAL SHIONOGI & CO., LTD. (JP) 1990-10-02 US disclosed
EP-0336143-A1 A new process for carbapenem intermediates SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) 1989-10-11 EP disclosed
US-4673752-A REDUCE INTRAOCULAR PRESSURE HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1987-06-16 US disclosed
US-4672115-A Process for preparing aminoacyllabdanes HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1987-06-09 US disclosed
US-4639446-A REDUCERS OF INTRAOCULAR PRESSURE HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1987-01-27 US disclosed
EP-0191166-A2 Aminoacyllabdanes, a process and intermediates for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1986-08-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053146-A1 PESTICIDAL COMPOSITIONS ACHE, DDT, PTMS FFAR3 1980/4885HDAC3 1373/4885HDAC1 2005/4885
US-20140057785-A1 PESTICIDAL COMPOSITIONS ACHE, DDT, PTMS FFAR3 3018/4885HDAC3 1230/4885HDAC1 1679/4885
US-20090181942-A1 TRICYCLIC COMPOUNDS FDFT1, COASY, HMGCR FFAR3 663/4885HDAC3 294/4885HDAC1 314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.